Browse Case Studies by
Case Studies in
- Corporate Governance
- Corporate Social Responsibility
- Economics
- Entrepreneurship
- Finance, Accounting & Control
- Leadership
- Marketing
- Organisational Behaviour / HRM
- Social Entrepreneurship
- Strategy
- All Case Studies »
Concept wise Case Studies
- Mergers, Acquisitions and Alliances - Vol. I
- Mergers, Acquisitions and Alliances - Vol. II
- Mergers, Acquisitions and Alliances - Vol. III
- Mergers, Acquisitions and Alliances - Vol. IV
- Airline Industry
- » All Concept wise Cases
Industry wise Case Studies
- Banking and Financing Services
- Retailing
- Energy and Utilities
- Oil and Gas Refining, Marketing and Distribution
- Commercial Aircraft Manufacturing
- » All Industry wise Cases
Region wise Case Studies
Mergers, Acquisitions, Alliances and Synergies Case Study
Case Title:
Novartis: Consolidation in Generics
Publication Year : 2005
Authors: Supratim Majumdar and Abhisekh Roy Chowdhury, Tirthankar Ray
Industry: Pharmaceutical
Region: Switzerland
Case Code: MAA0140K
Teaching Note: Not Available
Structured Assignment: Not Available
OR
Abstract:
The case discusses the mega acquisition of two big generic pharmaceutical companies, Hexal AG of Germany and Eon Labs of the United States (US), by the world’s second largest generic pharmaceutical company - Swiss based Novartis (Sandoz, the generic business division of Novartis). The acquisitions created the largest generic pharmaceutical company in the world, in terms of revenue. The case provides a detailed note on the global generic pharmaceutical industry, with a focus on its recent trends. After giving a brief note on Sandoz and the two acquired companies, the case discusses the rationale behind the acquisition and the benefits, which Novartis expected from it. It also explains the acquisition deal in detail and finally, discusses the possible challenges, which Novartis could face in the near future.
Pedagogical Objectives:
- To discuss the global Pharma industry
- To understand the reasons for growth of Generics
- To discuss about the acquisitions and the expected synergies
- To debate on the challenges that Novartis could face in the generic business.
Keywords : Mergers,Acquisitions,Alliances Case Study;Novartis; Sandoz; Hexal AG; Eon Labs; Pharmaceutical (pharma) industry; Generic drugs; Patented drugs; Acquisition; Intellectual property rights; Blockbuster drug; Big pharma; Cost competitiveness; Extended product portfolio; Vertical integration; Daniel Vasella
